PriceTargets.com logo

TScan Therapeutics - TCRX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.33
  • Forecasted Upside: 516.06%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$1.52 As of 04/30/2025 12:00 PM ET
▼ -0.075 (-4.72%)

This chart shows the closing price for TCRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
MarApr$1.59Closing price on 04/29/25:
Get New TScan Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TCRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TCRX

Analyst Price Target is $9.33
▲ +516.06% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for TScan Therapeutics in the last 3 months. The average price target is $9.33, with a high forecast of $15.00 and a low forecast of $3.00. The average price target represents a 516.06% upside from the last price of $1.52.

This chart shows the closing price for TCRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
4/247/2410/241/254/255/26$0.77$4.33$7.88$11$15Closing price on 04/29/25: $1.59High$15.00Average$9.33Low$3.00




Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in TScan Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/6/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/4/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/29/2025

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/8/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
3/14/2025Morgan StanleyReiterated RatingOverweight$10.00
3/7/2025BarclaysLower TargetOverweight ➝ Overweight$14.00 ➝ $3.00
3/6/2025HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
3/5/2025WedbushReiterated RatingOutperform$7.00
3/5/2025Needham & Company LLCLower TargetBuy ➝ Buy$11.00 ➝ $9.00
12/23/2024WedbushReiterated RatingOutperform$7.00
12/11/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
12/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
12/10/2024WedbushReiterated RatingOutperform$10.00 ➝ $7.00
11/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
11/12/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
11/6/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
11/5/2024WedbushReiterated RatingOutperform$10.00
8/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
8/12/2024WedbushReiterated RatingOutperform ➝ Outperform$10.00 ➝ $10.00
8/12/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
6/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
5/16/2024BTIG ResearchInitiated CoverageBuy$12.00
5/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00
5/13/2024WedbushReiterated RatingOutperform$10.00
5/13/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$11.00
4/23/2024WedbushReiterated RatingOutperform ➝ Outperform$10.00
4/17/2024WedbushReiterated RatingOutperform$10.00
3/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00
3/6/2024WedbushReiterated RatingOutperform$9.00 ➝ $10.00
2/26/2024WedbushReiterated RatingOutperform$9.00
2/1/2024WedbushReiterated RatingOutperform ➝ Outperform$9.00
1/4/2024WedbushReiterated RatingOutperform$9.00
11/27/2023Lifesci CapitalReiterated RatingOutperform
8/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$15.00
6/21/2023WedbushInitiated CoverageOutperform$8.00
3/9/2023HC WainwrightReiterated RatingBuy$15.00
5/10/2022HC WainwrightLower Target$21.00 ➝ $15.00
3/10/2022HC WainwrightReiterated RatingBuy$21.00
12/16/2021HC WainwrightInitiated CoverageBuy$21.00
8/13/2021CowenInitiated CoverageOutperform
8/10/2021BarclaysInitiated CoverageOverweight$22.00
8/10/2021Jefferies Financial GroupInitiated CoverageBuy$21.00
8/10/2021Morgan StanleyInitiated CoverageOverweight$22.00
(Data available from 4/30/2020 forward)

News Sentiment Rating

0.77 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/2/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/1/2024
  • 7 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/1/2024
  • 5 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/31/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/30/2025
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/1/2025
  • 4 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
3/31/2025
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/30/2025

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

TScan Therapeutics logo
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $1.52
Low: $1.48
High: $1.55

50 Day Range

MA: $1.58
Low: $1.10
High: $2.17

52 Week Range

Now: $1.52
Low: $1.02
High: $9.69

Volume

32,927 shs

Average Volume

357,694 shs

Market Capitalization

$85.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.09

Frequently Asked Questions

What sell-side analysts currently cover shares of TScan Therapeutics?

The following sell-side analysts have issued reports on TScan Therapeutics in the last twelve months: Barclays PLC, BTIG Research, HC Wainwright, Morgan Stanley, Needham & Company LLC, and Wedbush.
View the latest analyst ratings for TCRX.

What is the current price target for TScan Therapeutics?

0 Wall Street analysts have set twelve-month price targets for TScan Therapeutics in the last year. Their average twelve-month price target is $9.33, suggesting a possible upside of 516.1%. HC Wainwright has the highest price target set, predicting TCRX will reach $15.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $3.00 for TScan Therapeutics in the next year.
View the latest price targets for TCRX.

What is the current consensus analyst rating for TScan Therapeutics?

TScan Therapeutics currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TCRX will outperform the market and that investors should add to their positions of TScan Therapeutics.
View the latest ratings for TCRX.

What other companies compete with TScan Therapeutics?

Other companies that are similar to TScan Therapeutics include ORIC Pharmaceuticals, COMPASS Pathways, Alpha Teknova, Heron Therapeutics and Autolus Therapeutics. Learn More about companies similar to TScan Therapeutics.

How do I contact TScan Therapeutics' investor relations team?

TScan Therapeutics' physical mailing address is 830 WINTER STREET, WALTHAM MA, 02451. The company's listed phone number is 857-399-9500 and its investor relations email address is tscan@argotpartners.com. The official website for TScan Therapeutics is www.tscan.com. Learn More about contacing TScan Therapeutics investor relations.





Receive TScan Therapeutics News & Ratings Daily
Sign up to receive the latest news and ratings for TScan Therapeutics and its competitors with PriceTargets.com’s free daily newsletter.